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B cell lymphoma-6 (BCL6) is highly expressed in
germinal center B cells, but how its expression is
maintained is still not completely clear. Aryl hydro-
carbon receptor interacting protein (AIP) is a co-
chaperone of heat shock protein 90. Deletion of
Aip in B cells decreased BCL6 expression, reducing
germinal center B cells and diminishing adaptive im-
mune responses. AIP was required for optimal AKT
signaling in response to B cell receptor stimulation,
and AIP protected BCL6 from ubiquitin-mediated
proteasomal degradation by the E3-ubiquitin ligase
FBXO11 by binding to the deubiquitinase UCHL1,
thus helping to maintain the expression of BCL6.
AIP was highly expressed in primary diffuse large
B cell lymphomas compared to healthy tissue and
other tumors. Our findings describe AIP as a positive
regulator of BCL6 expression with implications for
the pathobiology of diffuse large B cell lymphoma.INTRODUCTION
Chaperone molecules play a crucial role in cellular homeostasis,
stabilizing labile proteins during periods of cellular stress. Heat
shock protein 90 (HSP90) is central to themaintenance of cellular
homeostasis (Taipale et al., 2010), and studies have indicated
that HSP90 can bind to 60% of the human kinome and 30% of
E3 ubiquitin ligases (Schopf et al., 2017; Taipale et al., 2014).Ce
This is an open access article undCo-chaperone proteins assist chaperone molecules in their sup-
ply and binding of specific client proteins to chaperone mole-
cules (Trepel et al., 2010), yet the precise molecular function
by which co-chaperones of HSP90 operate is still poorly under-
stood (Schopf et al., 2017).
Aryl hydrocarbon receptor (AHR) interacting protein (AIP) is a
conserved co-chaperone protein that binds to many proteins,
including AHR and HSP90 (Stockinger et al., 2014; Trivellin and
Korbonits, 2011). Individuals carrying monoallelic loss-of-func-
tion mutations in AIP (AIP carriers) are predisposed to young-
onset, aggressive, usually growth-hormone-secreting pituitary
adenomas that often result in acromegalic gigantism (Caimari
and Korbonits, 2016; Vierimaa et al., 2006). Our group set out
to understand the function of AIP in regulating adaptive immune
responses.
Because of the well-described role of AHR regulating T helper
17 (TH17) cells (Li et al., 2011; Veldhoen et al., 2008), we started
to examine the function of AIP on T cells and used the Rag1Cre/+
mouse strain to study its function in T cells. Unexpectedly, how-
ever, we noticed that deletion of Aip had an effect on B cells, and
we sought to investigate this function in more detail. Germinal
centers (GCs) are structures within secondary lymphoid tissues
that are vital for the development of effective adaptive immune
responses against pathogens (Allen et al., 2007; Victora and
Nussenzweig, 2012). GCs are challenging environments for
lymphocytes. B cells, upon activation, enter GCs where they
undergo rapid proliferation, class switch recombination, somatic
hyper-mutation, and affinity maturation, all of which place
considerable genotoxic stress on B cells (Allen et al., 2007; Vic-
tora and Nussenzweig, 2012). Inhibitors of HSP90 have been
shown to be effective in inducing apoptosis of B cell lymphomasll Reports 27, 1461–1471, April 30, 2019 ª 2019 The Authors. 1461
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. AIP Regulates Adaptive Immune Responses
(A–C) Aipfl/fl Cre+ (B) and Cre control (A) mice (Figures S1A and S1B) were
immunized with sheep red blood cells (SRBCs), and 10 days later, the size
(A and B) and number of germinal center (GC) B cells (BCL6+ area within
the IgD+ follicle; A and C) was determined. Aipfl/fl Cre+ mice and littermate
controls were immunized with NP-KLH absorbed with aluminum hydroxide
and examined 14 days after immunization.
(D and E) Serum was examined for the ability to bind to antigen with a high-
valence (low-affinity) (NP25) antigen (D) and a low-valence (high-affinity) (NP5)
antigen (E).
(F) The ratio of NP5:NP25 affinity antibodies from Aip
fl/fl Cre+ and littermate
controls was determined. See also Figure S5.
Scale bars, 100 mm. Results are from two or three independent experiments
with two to four animals per experiment. *p < 0.05; **p < 0.01.that have aGC origin and overexpress B cell lymphoma-6 (BCL6)
protein (Cerchietti et al., 2009).
BCL6 is a master regulator of GC B cell phenotype (Bunting
et al., 2016; Dent et al., 1997; Ye et al., 1997). By repressing tran-
scription of pro-apoptotic genes such as TP53 (Basso and Dalla-
Favera, 2015), BCL6 enables GC B cells to tolerate genotoxic
stress as they undergo rapid proliferation with somatic hyper-
mutation and class switch recombination (Basso and Dalla-
Favera, 2015). Accordingly, BCL6 upregulation is commonly
found in B cell lymphomas of GC origin (Baron et al., 1993; Basso
and Dalla-Favera, 2015).
Here, we deletedAip in mouse B cells, which led to suboptimal
adaptive immune responses, via altered AKT signaling and by
controlling the expression of BCL6 in GC B cells. We show that
AIP protects BCL6 from E3 ubiquitin ligase FBXO11-induced1462 Cell Reports 27, 1461–1471, April 30, 2019proteasomal degradation via binding the deubiquitinase
UCHL1. Together, these results demonstrate AIP as a positive
regulator of BCL6.
RESULTS
AIP Regulates Adaptive Immune Responses
To assess the impact of AIP on adaptive immune responses, we
crossed Aipfl/fl mice with Rag1Cre/+ mice generating mice car-
rying a conditional homozygous deletion of Aip in T and B cells
(Aipfl/fl;Rag1Cre/+) (referred to as Aipfl/fl Cre+ mice). This resulted
in deletion of AIP as determined by qPCR and western blot anal-
ysis (Figures S1A and S1B). These mice presented no sponta-
neous signs of pathology from birth to the age when they were
used for experiments (9–12 weeks).
To gain insight into whether Aip deficiency affected adaptive
immunity, Aipfl/fl Cre+ and Cre littermate controls were immu-
nized with sheep red blood cells (SRBCs) to induce a T cell-
dependent immune response and sacrificed 10 days later
(Sander et al., 2015). Analysis of the spleen revealed that in
contrast to the Aipfl/fl Cre+ animals, there was a significant in-
crease of the GC area or number of GCs in Cre mouse spleen
compared to Aipfl/fl Cre+ spleens following SRBC immunization
(p = 0.0146) (Figures 1A–1C).
We sought to determine whetherAipfl/flCre+mice had a defect
in the ability to generate high-affinity antibodies. Mice were
immunized with (4-hydroxy-3-nitrophenyl)-acetyl (NP)-keyhole
limpet hemocyanin (KLH) precipitated to aluminum hydroxide
(alum), and 2 weeks later, the capacity of serum immunoglobu-
lins to bind to high-valency antigen (NP25) and low-valency anti-
gen (NP5) was examined (Capasso et al., 2010). No difference
was detected between the Aipfl/fl Cre+ and Cremice in the gen-
eration of low-affinity antibody against NP-KLH (Figure 1D).
However, there was a significant reduction in the ability of Aipfl/fl
Cre+ mice to produce high-affinity antibody that could bind to
NP5 (p = 0.0002) (Figure 1E), and consequently, the ratio be-
tween NP5 and NP25 specific antibodies between Aip
fl/fl Cre+
and Cre mice was low (p = 0.026) (Figure 1F).
AIP Regulates GC Formation
The ability tomake antibody responses against T cell-dependent
antigens is dependent upon B cell differentiation into GC B cells
(Victora and Nussenzweig, 2012). Nonimmunized Aipfl/fl Cre+
had a significantly decreased percentage and ratio of GC B cells
(GL7+ CD95+) (the gating strategy and phenotype are shown in
Figures S1C–S1E) compared to littermate controls (p = 0.001)
(Figures 2A–2D). Of particular interest was that Aipfl/fl Cre+ GC
B cells demonstrated a significantly lower expression and ratio
of BCL6 compared to Cre GC B cells (p = 0.026) (Figures 2E
and 2F).
Conversely, Aipfl/fl Cre+ mice displayed a significant increase
in the percentage of non-GC B cells in secondary lymphoid tis-
sues (spleen and peripheral lymph nodes) along with increased
circulating B cells (Figure S2A). Despite the significant increase
in the number of B cells in the spleen, there was no difference
in the cellularity of the spleen between Cre and Aipfl/fl Cre+
mice, as Aipfl/fl Cre+ mice also displayed a decrease in the total
number of CD3+ T cells (Figures S2B–S2D). Similar to the spleen,
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Figure 2. AIP Regulates GC Formation
(A–C) GC B cells (B220+ GL7+ CD95+; in A) and percentage of GC B cells from
Aipfl/fl Cre+ mice (B; see also Figures S1C–S1F) and ratio of GCs between
Aipfl/fl Cre+ and Cre mice (C).
(D and E) Lower expression of BCL6 as determined by flow cytometry (D)
measuring the median fluorescent intensity (MFI; in E) (see also Figures
S2–S4). Grey histograms represent biological control by gating on naive (IgDhi)
B cells that do not express BCL6.
Results are from two or three independent experiments with two to four ani-
mals per experiment. *p < 0.05; **p < 0.01; ***p < 0.001.we also observed decreased GC B cells and BCL6 expression in
peripheral lymph nodes although there was an increase in GC
B cells from Peyer’s patches in Cre+ mice (Figure S2A).
Differences in GC B cells may be the result of altered B cell
development or the type of B cells produced. Examination of
naive, marginal zone and follicular B cell subsets revealed no dif-
ference between Cre and Aipfl/fl Cre+ mice (Figures S3A–S3D).
BCL6 has been reported to contribute to B cell lymphopoiesis
(Duy et al., 2010). Consequently, we examined developing
B cell subsets in the bone marrow of Cre and Aipfl/fl Cre+
mice but found no significant differences (Figure S3C). This indi-
cated that the difference we were observing in Aipfl/flCre+ B cellswas restricted to GC B cells. However, examination of the bone
marrow did reveal a lower percentage of IgM+B220hi B cells from
Aipfl/fl Cre+ mice (Figure S3D), suggesting that AIP impacted
upon B cells within the bone marrow. We did not observe any
changes in the immunoglobulin isotypes in serum or following
in vitro stimulation of Cre+ B cells (Figure S3E), indicating that
deficiency of AIP did not alter the production of antibodies or iso-
type switching.
As AIP was originally described as a co-chaperone for AHR
(Meyer and Perdew, 1999), we examined Ahrfl/fl mice crossed
with Rag1Cre/+mice to determine if they had a similar phenotype.
In agreement with a publication studying the role of AHR in
B cells (Villa et al., 2017), following SRBC immunization, we
found no differences in GCB cells, BCL6 expression, or antibody
production between Ahrfl/fl;Rag1Cre/+mice and littermate control
mice (Figures S4A–S4D). This suggested that AIP was acting
independently of AHR to regulate GC B cells and BCL6.
Given the suggested role of AIP in regulating T cell-dependent
antigen responses, we tested if there might be a reduced
T response to T cell-independent antigens in Aipfl/fl Cre+ mice.
To test this, we immunized mice with an NP-Ficoll conjugate, a
T cell-independent antigen that recruits marginal zone B cells
to produce a low-affinity extra-follicular antibody response (Gar-
cı´a de Vinuesa et al., 1999). 10 days after immunization, we
analyzed mice and measured the amount of NP-specific immu-
noglobulin M (IgM), IgG, and IgG3 in the serum by ELISA. Aipfl/fl
Cre+ mice could make NP-specific IgM (p = 0.0001) and IgG
(p = 0.029) (Figures S5A and S5B), but the titer of the antibodies
against NP was significantly lower compared to Cremice. IgG3
is produced in response to T cell-independent antigens (Garcı´a
de Vinuesa et al., 1999), and Aipfl/fl Cre+ mice made significantly
less (p = 0.0031) IgG3 compared to Cre mice (Figure S5C),
despite having normal levels of marginal zone B cells. Examina-
tion of the percentage of NP-specific B cells by flow cytometry
showed that Aipfl/fl Cre+ mice had significantly decreased
percentage of NP-specific plasmablasts (B220+/ CD138+)
compared to Cre mice (p = 0.028) (Figures S5D and S5E).
Together, these results demonstrated that AIP was required for
the generation of development of antibody responses in both
the GC and extra-follicular sites.
AIP Regulates GC Organization and AKT Signaling in GC
B Cells
GC B cells undergo repeated cycles of rapid proliferation in the
dark zone (DZ) followed by a resting state in the light zone (LZ)
where the cells can reencounter, their antigen presented by
follicular-dendritic cells. If the recognition is successful, then B
cell progress to become memory B cells or plasmablasts or
reenter the DZ to further increase their B cell receptor affinity (Al-
len et al., 2007; Mesin et al., 2016; Victora and Nussenzweig,
2012). DZ and LZGCB cells can be distinguished by flow cytom-
etry using themarkers including CXCR4 (DZ) and CD86 (LZ) (Vic-
tora et al., 2010). Using this method, we analyzed GC B cells and
found, in agreement with other studies, a ratio of 2 between
DZ and LZ B cells in wild-type GC B cells. In contrast, there
was a significantly reduced DZ/LZ ratio between Aipfl/fl Cre+
and Cre mice (p = 0.001) (Figures 3A and 3B). Immunofluores-
cent analysis of Cre and Aipfl/fl Cre+ spleen sections revealedCell Reports 27, 1461–1471, April 30, 2019 1463
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C Figure 3. AIP Regulates GCOrganization and
AKT Signaling in GC B Cells
(A) Expression of dark zone (DZ) (CXCR4+) and light
zone (LZ) (CD86+) GC B cells from immunized Aipfl/fl
Cre+ and littermate controls.
(B) Ratio of DZ and LZ GC B cells f.
(C) Spleen sections from Aipfl/fl Cre+ and Cre
mice were analyzed by immunofluorescence for LZ
CD19+ BCL6+ and DZ AID+ BCL6+ areas of GCs.
(D–F) The phosphorylation of AKT (serine 473) was
determined in LZ GC B cells from Aipfl/fl Cre+ and
littermate controls (D) and the percentage of pAKT
(E) and MFI (F) determined. Grey histograms are
gating on IgD+ naive B cells used as a biological
control.
(G and H) IgD B cells from Cre+ and Cre mice
were stimulated with anti-IgM (10 mg/mL) and
examined for the expression of phosphorylated AKT
from 5 to 60 min post-stimulation (G) and the per-
centage increase from time zero determined (H).
See also Figure S6. Grey histograms show expres-
sion at time zero (T0).
Scale bars, 50 mm. Results are from two or three
independent experiments with one or two mice
per experimental group. *p < 0.05; **p < 0.01;
***p < 0.001.that the area of the DZ (activation-induced deaminase [AID]+ and
BCL6+ cells) was smaller in Aipfl/fl Cre+ mice than in Cre mice
(Figure 3C).
Phosphatidylinositol 3-kinase (PI3K) signaling contributes to
the segregation of the DZ and LZ by phosphorylating AKT (serine
473) in LZ GC B cells, resulting in decreased expression of the
chemokine receptor CXCR4 (Dominguez-Sola et al., 2015;
Sander et al., 2015).We observed a significant decrease in phos-
pho-AKT expression in LZ GC B cells from Aipfl/fl Cre+ mice
compared to Cre mice (p = 0.003) (Figures 3D–3F). AIP ap-
peared to regulate the AKT pathway, as in vitro anti-IgM stimula-
tion of Aipfl/fl Cre+ B cells revealed that while AKT was rapidly
phosphorylated in both Aipfl/fl Cre+ and Cre deficient B cells
following stimulation, AKT phosphorylation was subsequently
reduced at a faster rate in Cre+ B cells than in Cre B cells (Fig-
ures 3G and 3H). AIP appeared to be specifically regulating AKT,
as the extracellular signal regulated kinase (ERK) and SYK path-
ways were unaffected (Figures S6A and S6B).
AIP Regulates GC B Cells Independently of T Cells
Aswe had conditionally deletedAip in both T andB cells, it raised
the possibility that the defects observed in Aip-deficient B cells
might be consequent to altered T cell help. We observed a
decrease in T follicular helper (TFH) cells in Aip
fl/fl Cre+ mice
(data not shown). TFH cells are dependent on BCL6 for their
development (Huang et al., 2013), and we observed a decrease1464 Cell Reports 27, 1461–1471, April 30, 2019in BCL6 expression in Aipfl/fl Cre+ mice
(data not shown). To address this issue,
we crossed Aipfl/fl mice with Cg1-Cre
mice to specifically delete Aip in GCB cells
(Calado et al., 2012). Mice were immunized
with SRBCs, and 10 days later, the per-centage of GC (GL7+ CD95+) B cells and the expression of
BCL6 were determined. As predicted, conditional deletion of
Aip in GC B cells resulted in a lower percentage of GC B cells
with a lower expression of BCL6 (Figures 4A–4D) and a
decreased ratio of DZ to LZGCBcells (Figure 4E) and decreased
anti-SRBC IgG (Figure 4F). Together, these results indicated that
AIP regulated GC B cells and BCL6 expression independently of
T cells.
AIP Protects BCL6 from FBXO11-Mediated Proteasomal
Degradation
We sought to investigate the mechanism by which AIP sustains
BCL6 expression in GC B cells. The E3 ligase containing F box
protein O11 (FBXO11) has been shown to target BCL6 for ubiq-
uitin-mediated proteasomal degradation (Duan et al., 2012). This
observation attracted our interest as a potential mechanism by
which AIP could regulate BCL6, as AIP had previously been
shown to protect AHR from ubiquitin-mediated degradation (Ka-
zlauskas et al., 2000) and AIP has recently been found to bind to
FBXO3 (Herna´ndez-Ramı´rez et al., 2016). We hypothesized that
AIP was protecting BCL6 from ubiquitin-mediated proteasomal
degradation via FBXO11.
Immunoprecipitation (IP) analysis of HEK cells transfected
with MYC-tagged AIP and FLAG-tagged FBXO11 revealed that
AIP could bind to FBXO11 and BCL6, thereby revealing a poten-
tial mechanism of action (Figures 5A and 5B). Ubiquitin E3
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Figure 4. AIP Regulates GC B Cells Independently of T Cells
(A and B) GC B cells (GL7+ CD95+) from Aipfl/fl mice crossed with Cg1Cre/+ mice and examined at baseline (open circles) or following immunization with 2 3 109
SRBCs (filled circles) 10 days later (A) and the expression of BCL6 was assessed by flow cytometry (B).
(C and D) The percentage of GC B cells (C) and MFI from baseline (unimmunized; D) and immunized Aipfl/fl; Cg1Cre/+ mice was determined.
(E) Expression and ratio of DZ (CXCR4+) and LZ (CD86+) GC B cells from immunized mice.
(F) Serum anti-SRBC IgG determined by incubating serially diluting serum from Cre and Cre+ mice.
Results are from two independent experiments with three mice per group. *p < 0.05; **p < 0.01.ligases are often found in association with deubiquitinases
(DUBs) of the same substrate (Komander et al., 2009). We there-
fore wanted to know if AIP associated with any DUBs that might
regulate BCL6 expression. Mass-spectrometry analysis had re-
vealed that AIP could bind to the DUB UCHL1 (Herna´ndez-Ram-
ı´rez et al., 2016). UCHL1 is induced in GC B cells and cooperates
with BCL6 to promote a mouse model of lymphoma and is asso-
ciated with an aggressive subset of diffuse large B cell lym-
phoma (DLBCL) (Bedekovics et al., 2016; Hussain et al., 2010).
We hypothesized that AIP might support the expression of
BCL6 by binding UCHL1 and support the deubiquitination of
BCL6.
Using the functionally relevant DLBCL cell line OCI-LY7, we
found that AIP could bind to UCHL1 (Figure 5C) and that
UCHL1 could bind to BCL6 (Figure 5D), indicating that UCHL1
could be responsible for maintaining BCL6 expression. In agree-
ment with Duan et al. (2012), we found that OCI-LY7 cells ex-
pressed FBXO11, although interestingly, using these cells, we
found that FBXO11 could not directly bind to BCL6 (Figure 5E).
To determine if FBXO11-mediated degradation of BCL6 could
be modulated by AIP, we transfected HEK cells with epitope-tagged FBXO11, BCL6, AIP, and ubiquitin plasmids. The addi-
tion of AIP reduced FBXO11-mediated ubiquitin conjugation
to BCL6. The absence of AIP resulted in an increase in BCL6
ubiquitination (in the presence of FBXO11) and subsequently
decreased BCL6 expression, recapitulating what we observed
in Aip-deficient B cells (Figure 5F).
BCL6 has not been described as being a substrate for UCHL1,
so we tested whether UCHL1 could deubiquitinate BCL6. Trans-
fection of HEK cells revealed that UCHL1 could deubiquitinate
BCL6 only in the presence of AIP (Figure 5G), indicating that
AIP regulated the function of UCHL1. To confirm the IP results,
we performed confocal microscopy using the OC1-LY7 lym-
phoma cell line. AIP co-localized with BCL6, UCHL1, and
FBXO11. BCL6 co-localized with FBXO11 and, to a greater
extent, UCHL1 (Figure 5H). Together, these results revealed
the mechanism by which AIP regulated BCL6 expression in GC
B cells.
AIP Is Overexpressed in Human DLBCLs
Examination of the cbioportal database for cancer genomics
(http://www.cbioportal.org; Cerami et al., 2012) revealed thatCell Reports 27, 1461–1471, April 30, 2019 1465
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AIP expression was higher in DLBCLs than in other cancers and
tumors (Figure 6A). Histological analysis of primary DLBCL bi-
opsy samples revealed that AIP expression was significantly
increased compared to control (reactive lymph node) samples
(p < 0.0001) (Figure 6B). Data obtained from genomicscape
(http://www.genomicscape.com/) revealed that DLBCL patients
with high AIP expression had significantly (p = 0.002) reduced
survival compared to those with low AIP expression, indicating
that increased AIP expression contributed to the morbidity of
DLBCL (Figure 6C). Western blot analysis revealed that AIP
was expressed in a number of DLBCL cell lines and that its
expression matched BCL6 expression (Figures 6D and 6E).
To determine if knockdown of AIP in lymphoma cells affects
their viability, we performed lentiviral knockdown of AIP in
OC1-LY7 DLBCL lymphoma cells. Knockdown of AIP in OC1-
LY7 cells resulted in decreased AIP and BCL6 expression and
decreased the viability of the DLBCL lymphoma cells (Figure 6F).
Based upon these results, we propose that AIP positively reg-
ulates BCL6 expression by binding to the DUB UCHL1, thereby
preventing FBXO11-mediated ubiquitination of BCL6 and
contributing to the maintenance of BCL6 expression in GC
B cells and DLBCLs (Figure 6G).
DISCUSSION
Lymphocytes need to maintain cellular homeostasis as they
navigate a range of genotoxic events and environments. A
particularly challenging environment is within GCs, where B cells
undergo rapid proliferation, class switching, and somatic hyper-
mutation. How B cells preserve cellular homeostasis in this
environment is still not completely clear.
We provide evidence that AIP is required for mounting immune
responses against T cell-dependent and, to a lesser extent,
T cell-independent antigens and the generation of high-affinity
antibodies. Consequently, we found that Aipfl/fl Cre+ mice and
conditional deletion of Aip in GC B cells display a significant
reduction in the percentage of GC B cells and decreased
BCL6 expression, partly providing an explanation for impaired
adaptive immune responses.
We focused on AIP regulation of BCL6, as it was an obvious
starting candidate when we observed decreased GC B cells in
Aipfl/fl Cre+ mice. In line with our observations, Bcl6-deficient
mice have impaired GC responses similar to the phenotype we
observed (Huang et al., 2013; Ye et al., 1997). However, not allFigure 5. AIP Protects BCL6 from FBXO11-Mediated Proteasomal Deg
(A) HEK293T cells were transfected with either a FLAG-tagged FBXO11 or empty
extracts (WCEs) were subjected to immunoprecipitation (IP) using FLAG antibody
and 4).
(B) HEK293T cells were transfected with either FLAG-tagged BCL6 or EV-FLAG,
subjected to IP using FLAG antibody (rows 1 and 2), the and the rest of the WCE
(C) OCI-LY7 DLBCL cells were lysed and immunoprecipitated with antibodies to
(D) OCI-LY7 DLBCL cells were lysed and immunoprecipitated with antibodies to
(E) OCI-LY7 DLBCL cells were lysed and immunoprecipitated with antibodies to Ig
used as a loading control.
(F) HEK293T cells were transfected with MYC-tagged AIP or EV-MYC, FLAG-t
Where indicated, cells were treated with MG132 post-transfection for 2.5 h to in
(G) HEK cells were transfected as in (F) and FLAG-tagged UCHL1. Cells were ha
(H) OC1-LY7 cells were stained with AIP, BCL6, UCHL1, and FBXO11. DAPI wathe effects that we see in our Aipfl/fl Cre+ mice can be attributed
to decreased expression of BCL6; for example, reduced extra-
follicular immune responses and reduced AKT phosphorylation
are not features of Bcl6-deficient mice, and to our knowledge,
BCL6 is not known to regulate the migration of B cells.
Aip-deficient B cells initially phosphorylated AKT similar to
wild-type B cells; however, AKT phosphorylation was rapidly
lost in Aip-deficient B cells in contrast to wild-type B cells. We
have observed similar defects in AKT signaling following insulin
stimulation in GH3 pituitary cells with lentiviral Aip knockdown
(M.K. and O.H., unpublished data). HSP90 has been found to
regulate AKT expression and phosphorylation (Sato et al.,
2000), and UCHL1 has also been found to regulate AKT signaling
(Hussain et al., 2010), and we are currently determining how AIP
regulates AKT signaling.
AIP is a co-chaperone for AHR (Kazlauskas et al., 2000; Lees
et al., 2003). We were therefore surprised to find that conditional
deletion of Ahr in B and T cells did not match the phenotype we
observed in Aipfl/fl Cre+ mice. This indicated that AIP was acting
independently of AHR to regulate GC B cells. This finding is sup-
ported by Villa et al., who showed that AHR supported B cell pro-
liferation but was not necessary for T cell-dependent or indepen-
dent immune responses (Villa et al., 2017). However, a recent
publication reports that AHR was important in suppressing
T cell-dependent and T cell-independent immune responses
(Vaidyanathan et al., 2017). The reasons for the different re-
sponses from Ahr null B cells are not clear at present.
As BCL6 is an important oncoprotein, there is considerable in-
terest in how it is regulated. BCL6 expression can be controlled
via post-translational mechanisms, including phosphorylation
(Niu et al., 1998), mRNA stability, and nuclear export by eIF4Ae
(eukaryotic translation initiation factor 4E) (Culjkovic-Kraljacic
et al., 2016), in response to DNA damage (Phan et al., 2007)
and stabilization by HSP90 (Cerchietti et al., 2009). Mitogen-acti-
vated protein kinase (MAPK) signaling following B cell receptor
stimulation has been shown to be involved in the degradation
of BCL6 (Niu et al., 1998). We saw no evidence of increased
ERK signaling in Aip null B cells compared to wild-type B cells
following anti-IgM stimulation, suggesting that this is not the
mechanism by which AIP regulated BCL6 expression.
FBXO11 has been found to target BCL6 for ubiquitin-mediated
degradation and mutations in FBXO11 associated with lym-
phoma (Duan et al., 2012). We found that AIP and the
FBXO11-containing E3 ligase complex co-immunoprecipitationradation
vector (EV-FLAG), together with MYC-tagged AIP. A majority of the whole-cell
(rows 1 and 2), and the rest of the WCEs were used in immunoblotting (rows 3
together MYC-tagged AIP (Leontiou et al., 2008). A majority of the WCEs were
s were used in immunoblotting (rows 3 and 4).
IgG, AIP, UCHL1 and immunoblottedfor AIP and UCHL1.
IgG, BCL6, UCHL1 and immunoblotted for BCL6 and UCHL1.
G, FBXO11 and BCL6 and immunoblotted for BCL6 and FBXO11. b-actin was
agged FBXO11, HIS-tagged BCL6, and hemagglutinin (HA)-tagged ubiquitin.
hibit proteasomal degradation.
rvested and subjected to IP BCL6. Corresponding WCEs are shown.
s used as a nuclear stain. Arrowheads show areas of co-localization.
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(co-IP), and we demonstrated that AIP inhibited FBXO11-medi-
ated ubiquitination of BCL6. Intriguingly, mice deficient for
FBXO11 in their B cells show a phenotype that is the opposite
of ours; namely, an increased percentage of GC B cells and
DZ GC B cells. These mice are also more prone to developing
lymphoproliferative disease (Schneider et al., 2016). The DUB
UCHL1 has been found to be expressed in GC B cells and lym-
phoma cells (Hussain et al., 2010), but the functional relevance of
this expression of UCHL1 has not been determined. We found
that UCHL1 could deubiquitinate BCL6, but only in the presence
of AIP, indicating that AIP regulated the function of UCHL1. The
precise mechanism by which AIP regulates UCHL1 will be the
focus of future research, but DUBs often require co-factors to
function (Komander et al., 2009).
AIP is a co-chaperone of HSP90 that can bind to proteins that
control GC B cell phenotype, including c-MYC, STAT5, and nu-
clear factor kB (NF-kB), in addition to BCL6 (Cerchietti et al.,
2009; Hertlein et al., 2010; Paul et al., 2013; Weigert et al.,
2012). We have not ruled out the possibility that AIP can regulate
these molecules, as these might contribute to the phenotype we
observe in Aip-deficient B cells. This is the focus of ongoing
research.
Ubiquitin E3 ligases often work in close proximity to DUBs to
provide precise control over substrate proteins (Komander
et al., 2009). Increased expression of the DUB UCHL1 has
been associated with development of lymphoma and is a posi-
tive regulator of AKT signaling (Bedekovics et al., 2016; Hussain
et al., 2010), but in B cells, its substrates and how it is regulated
have not been identified. We found UCHL1 to be a binding part-
ner of AIP and BCL6, indicating that it might function to help
maintain BCL6 expression in GC and DLBCL cells.
There is significant evidence that chaperones are important
regulators of protein quality control, helping ubiquitin E3 ligases
and DUBs recognize their target proteins (Kriegenburg et al.,
2012; Lee et al., 2014; Manjarrez et al., 2014; Morales and
Perdew, 2007; Perrody et al., 2016). Chaperone molecules
contribute to the pathobiology of cancers by protecting labile
proteins from being degraded and supporting signaling path-
ways that cancer cells are dependent upon (Polier et al., 2013;
Whitesell and Lindquist, 2005; Zong et al., 2015). We found AIP
to be predominantly expressed in DLBCL compared to other tu-
mors and overexpressed in DLBCL biopsy samples compared to
tonsil tissue, indicating that AIP might contribute to DLBCL pa-
thology. Knockdown ofAIP in DLBCL cells resulted in decreased
viability of DLBCL cells, indicating that targeting AIP could be
used as a potential treatment for DLBCL.Figure 6. AIP Is Overexpressed in Human DLBCLs
(A) AIP is expressed in many tumors, and AIP was found to be most highly expre
(B) AIP staining from reactive lymph nodes (n = 88 mean 13 ± 2.5) and DLBCL bi
(C) Survival analysis of DLBCL patients with high and low AIP expression. Data o
(D) BCL6 and AIP protein expression in DLBCL cell lines.
(E) Ratio between AIP and BCL6 expression. EBV, Epstein-Barr-virus-infected B
(F) Lentiviral delivery of scrambled or shRNAi against Aip to OC1-LY7 cells. Cells w
cell viability were analyzed by flow cytometry.
(G) Diagram showing the interaction between FBXO11, UCHL1, BCL6, and AIP.
UCHL1 to deubiquitinate BCL6, thus maintaining its expression. In the absenc
degradation. ***p < 0.0001 (a Mann-Whitney U test).How BCL6 expression is maintained is still not completely un-
derstood. The data presented here reveal that AIP is a positive
regulator of BCL6 protein expression, which is commonly upre-
gulated in B cell lymphomas, and show that AIP binds to an E3
ligase (FBXO11) and a DUB (UCHL1), both of which have been
associated with DLBCL pathobiology. Therefore, AIP is a poten-
tial therapeutic target to treat DLBCLs.
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Recombinant mouse IL-4 Peprotech Cat # 214-14
Experimental Models: Cell Lines
HEK293T ATCC CRL-3216
OC1-LY7 ATCC ACC688
SUDHL6 Barts Cancer Institute N/A
OC1-LY1 Barts Cancer Institute N/A
DoHH2 Barts Cancer Institute N/A
Karpas422 Barts Cancer Institute N/A
A20 Barts Cancer Institute N/A
EBV of healthy control Korbonits Lab
(Herna´ndez-Ramı´rez et al., 2016)
N/A
Experimental Models: Organisms/Strains
Aip flox/flox mice Jackson Laboratories 013195
Ahr flox/flox mice Stockinger Lab, Crick Institute,
London (Li et al., 2011)
N/A
Rag1 Cre mice Stockinger Lab, Crick Institute,
London (Li et al., 2011)
N/A
Cg1 Cre mice Calado Lab, Crick Institute,
London (Calado et al., 2012)
N/A
Oligonucleotides
Rag1 KI CRE F: 50-TTTGTTTTTGTTTGCTTGTTTGA Sigma N/A
Rag1 WT R: 50-ATCCTTCTCCTTCTGTGCTTCTT Sigma N/A
Rag1 KI CRE (V2): 50-AATGTTGCTGGATAGTTT
TTACTGC
Sigma N/A
Cg1 IgG1 Kpn1 (WT): 50 -TGTTGGGACAAACG
AGCAATC
Sigma N/A
Cg1 Cre Cre13 (CRE) 50-GGTGGCTGGACCAA
TGTAAATA
Sigma N/A
Cg1 Cre IgG1Rev (Common) 50-GTCATGGCAAT
GCCAAGGTCGCTAG
Sigma N/A
Aip: F 50-CAATCCCCCACTGTCACTT Sigma N/A
Aip: R- 50-TCACCCCTCCCACTGACTAC Sigma N/A
Aip Smart vector lentiviral shRNA Dharmacon N/A
Recombinant DNA
AIP-MYC pcDNA3.1 Korbonits Lab (Leontiou et al., 2008) N/A
BCL6-FLAG pcDNA3.1 SinoBiological Cat # NM_138931
FBXO11-FLAG pCMV3 SinoBiological Cat # BC130445
Ub-HA pRK5 Nightingale Lab (QMUL, London) N/A
UCHL1-FLAG SinoBiological Cat # NM_004181.4
Software and Algorithms
PRISM version 6 Graphpad.com N/A
FlowJo Version 9.3.1 Tree Star N/A
Ariol Software Leica Biosystems N/A
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Oliver
Haworth (o.haworth@westminster.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Aipfl/fl (Jackson laboratories) and Ahrfl/fl mice (Li et al., 2011) were crossed with Rag1Cre/+ mice (a kind gift from Brigitta Stockinger,
Crick Institute) to specifically delete Aip in Rag1 expressing cells (T and B cells) as previously described (Li et al., 2011), and Cg1Cre/+
mice (a kind gift from Dinis Calado, Crick Institute; Calado et al., 2012) to specifically delete Aip in GC B cells. Male and female mice
were born to expected Mendelian ratios and had no signs of any abnormalities until they were used at 9-11 weeks of age. Male and
female mice were randomly assigned to experimental groups. All mice were maintained in a barrier facility and all experiments were
approved and performed adhered to Home Office regulations (Guidance on the Operation of Animals, Scientific Procedures Act,
1986) and Queen Mary University of London ethics committee on the use of animals for research. Genotyping was performed using
the primers listed in Key Resources Table.
Cell lines
HEK293T (ATCC), OC1-LY7 (ATCC), SUDHL6, OC1-LY1, DoHH2, Karpas422, A20 (Barts Cancer Institute), human EBV (Herna´ndez-
Ramı´rez et al., 2016)
Tissue array
Human DLBCL tissuemicroarray (33 patients, age range 23-86y). Sample collection approved by the local Human Ethics Committee.
METHOD DETAILS
Immunizations
Mice were immunized in the peritoneumwith either 23 109 fresh SRBCs (TSC Biosciences Ltd, UK) and 10 days later sacrificed as in
Calado et al. (2012). NP (4-hydroxy-3-nitrophenyl-acetyl) conjugated to Keyhole Limpet Hemocyanin (KLH) or to Ficoll (Biosearch
Technologies, Petaluma, USA) and examined 14 days later (Capasso et al., 2010; Garcı´a de Vinuesa et al., 1999).
Collection and staining of tissues
Mouse tissues were stained using primary antibodies (Key Resources Table). Nuclei were detected using Hoechst 33258 and FITC
was amplified using goat anti-FITC Alexa Flour 488 (Life Technologies). For AID staining a tertiary step of donkey anti-goat FITC
(Jackson ImmunoResearch) was used. Slides were imaged using the Zeiss LSM 780 Confocal Microscope and Zeiss Axio Scan.Z1.
Image analysis was performed using Zeiss Zen 2012 software to determine germinal center, follicular and spleen area. Plasma cells
were counted by hand.
IgM stimulation of B cells
Spleen cells were stimulated with anti-mouse IgM (10mg/ml) (Jackson ImmunoResearch). At the end of the experiment, cells were
immediately put on ice, fixed and permeabilized using and analyzed by flow cytometry for phosphorylated signaling molecules.
In vitro cell culture of B cells
B cells were isolated by MACS isolation or cell sorting and 105/well were stimulated with 1 mg/ml anti-CD40 (Jackson
ImmunoResearch) and 25ng/ml IL-4 (eBioscience) and the cells examined 38, 72 and 96 hours after stimulation.
Flow cytometry
Single-cell suspensions of tissues were prepared by passing spleen and lymph nodes through a 70 mm cell strainer and incubated
with anti-CD16/32 (2.4G2) to block non-specific binding and then stainedwith antibodies (Key Resources Table). Cells were fixed and
permeabilized using the Biolegend intracellular staining and permeabilization buffer according to the manufacturer’s instructions.
Samples were acquired on an LSR Fortessa (BD) and the data analyzed using FlowJo software version 9.3.1 (Tree Star, Inc, Ashland,
USA).
Detection of sheep red blood cell-specific antibodies
This was performed as described in Calado et al. (2012). Serum from mice was serially diluted and incubated with SRBC for
20 minutes on ice washing in cold phosphate-buffered saline and staining the SRBCs with a phycoerythrin (FITC)-conjugated
anti-mouse IgG antibody and the samples were analyzed by flow cytometry.e3 Cell Reports 27, 1461–1471.e1–e4, April 30, 2019
Western blotting
Cells were re-suspended in cold RIPA lysis buffer (50mMTris-HCl, pH 8.0, 10%sodiumdeoxycholate, 10%SDS, 150mMNaCl, 5mM
EDTA, pH 8.0), supplemented with a mixture of protease inhibitors (1mM phenylmethylsulphonyl fluoride, 10mM sodium fluoride,
1mM sodium vanadate, 1mg/mL Leupeptin, 2mg/ml Aprotinin, 1M B-glycer). Samples were separated by standard SDS-polyacryl-
amide gel electrophoresis (SDS–PAGE). Protein extracts (40 mg total protein/lane) were fractionated on 8%SDS polyacrylamide gels
and transferred to nitrocellulose membranes before being incubated with primary antibodies.
Immuno-precipitation
HEK293T cells (ATCC) (0.53 106) were plated in 10cm dishes and the next day transfected with AIP and BCL6 epitope tagged plas-
mids using Fugene (Promega) according to the manufacturer’s instructions. The next day, cells were washed with 1ml phosphate-
buffered saline and lysed using lysis buffer (5M NaCl, 1M Tris, 75% glycerol, 0.5M, EDTA, NP-40, sodium fluoride, dH2O and sodium
vanadate). Subsequently, the cell lysates underwent immune-precipitation executed under cold conditions (4C) throughout. Cell ly-
sates were subjected to an overnight incubation on a rotator with the primary antibody followed by a two-hour incubation with 50 mL
of protein A and G agarose beads. Pellets were washed with 500 mL lysis buffer five times, re-suspended in 40 mL lysis buffer and
10 mL 4 3 SDS sample buffer. Samples were boiled at 95C for 5 minutes and left to cool on ice to proceed with SDS-PAGE for im-
muno-blotting.
AIP staining of DLBCL tissue biopsies
Tissuemicroarrays containing either reactive lymph node (tonsil) or DLBCL samples from the Bart’s Cancer Institute tissue bankwere
immuno-stained for AIP and tissue microarrays images were taken using an Olympus BX61 microscope and analyzed using Ariol
software for the staining intensity of AIP.
Lentivirus production and transfection of B cells
Lentivirus was produced using the protocol described in Kutner et al. (2009) in accordance with institutional guidelines using lenti-
virus. ShRNAi sequences against human AIPwere purchased from Dharmacon/GE Life sciences. Early passage OC1-LY7 cells (less
than passage 10) (ATCC) grown in Iscove’s Modified Dulbecco’s Medium supplemented with 20% FBS, were transduced with lenti-
virus containing a scrambled sequence or shRNAi against AIP using themethod described by Boulianne et al. (2017). 2.53 105 OC1-
LY7 cells were spin-oculated with 50 mL of lentivirus supernatants supplemented with 5mg/ml polybrene (Sigma) and spun for
90 minutes at 2300 rpm. After 4 hours, media was replaced with fresh media (Iscove’s modified Dulbecco’s Medium supplemented
with 10% FBS) and 24 hours later the cells were examined. Transfection efficiency using green fluorescent protein was shown to be
85%.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using Prism software (Version 6). Un-paired two-tailed Student’s t test, Mann-Whitney test and
2-way ANOVA test were used as appropriate. Significance was taken as p < 0.05. Statistical details of the experiments can be found
in the Figure Legends and Results. Data are plotted asmean ±SEMwith n the number of biological replicates. On figures significance
is marked as * p < 0.05, ** p < 0.01, ***p < 0.001.Cell Reports 27, 1461–1471.e1–e4, April 30, 2019 e4
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Figure S1. RAG1 Cre deletion of Aip and phenotype of GC B cells; related to Figure 1
(A) qPCR and (B) Western blot analysis of Aip from GC B cells from Aipfl/fl Cre+ and Aipfl/fl Cre- mice. Data
are plotted as mean ± SEM. (C) gating strategy to identify and analyze GC B cells. (D) size (FSC), (E)
BCL2 expression, (F) proliferation of GC B cells from Cre- and Cre+ mice.
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Figure S2. Increased B cells in the periphery of Aipfl/fl Cre+ mice; related to Figure 2
(A) Percentage of B cells in spleen, lymph nodes and circulating blood of B220+ IgD+ B cells from Aipfl/fl Cre+
mice compared to WT mice. Data shown as percentage ± SEM. Total number of B220+ IgD+ B cells (B)
and total number of splenocytes (C). Total number of CD3+ T cells (D). Results are from 4-5 independent
experiments, 2-3 mice per experimental group.
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Figure S3. No difference in Marginal Zone or Follicular B cells or B cell development in Aipfl/fl Cre+
mice; related to Figure 2
(A) Marginal zone (MZ) (CD21+ CD23-) and Follicular (FO) CD21- CD23+) B cells were analysed by flow
cytometry. (B) Expression of IgM or IgD on B cells from WT and Aipfl/fl Cre+ mice. (C) Bone marrow from the
femurs of Aipfl/fl Cre+ and Cre- mice and were analyzed for different stages of B cell development by flow
cytometry. B220+ cells were stained with CD43 and CD24. The CD24+ cells were divided into different sub-
populations depending upon their expression of IgM and IgD. (D) Bone marrow from the femurs of Aipfl/fl Cre+
and Cre- mice and were analyzed for B220hi IgM+/- B cells by flow cytometry. There was a significant
reduction in the percentage of B220hi IgM+ B cells from Aipfl/fl Cre+ mice compared to Cre- mice. (E) serum
from Cre- and Cre+ mice were examined by ELISA for immunoglobulin isotypes. B cells from Cre- and Cre+
were isolated and stimulated in vitro in the presence of anti-IgM, anti-CD40 and IL-4 and the percentage of
proliferating cells (blasts) (F), IgG1 expression (G) and CD138 (H) examined at 48, 72 and 96 hours post
stimulation by flow cytometry. 2-3 independent experiments, Results are from 2-3 mice per experimental
group.
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Figure S4. AHR∆TB mice have normal GC B cells and immune responses towards SRBCs; related to
Figure 2
(A) AHR∆TB and Cre- mice were immunized with SRBCs and the percentage of GC B cells (B220+ IgD- GL-
7+) examined. (B) BCL6 expression determined from AHR-/- and AHR+/+ IgD- B cells. (C) DZ (CXCR4+) and
LZ (CD86+) GC B cells from AHR∆TB and Cre- B cells and the DZ/LZ ratio. (D) Serum from AHR∆TB and Cre-
mice immunized with SRBCs were serially diluted and incubated with SRBCs and the amount of IgG bound
determined by flow cytometry. Results are from two independent experiments, 2-3 mice per experimental
group. Data are plotted as mean± SEM.
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Figure S5. Aipfl/fl Cre+ mice decreased extra-follicular immune responses; related to Figure 1
Aipfl/fl Cre+ and Cre- mice were immunized with NP-Ficoll and analyzed 14 days later NP-specific serum (A)
IgM, (B) IgG and (C) IgG3 analyzed by ELISA. Data are plotted as mean ± SEM. (D-E) Percentage of NP-
specific plasmablasts (B220+/- CD138+) analyzed by flow cytometry. Representative FACS plots from at
least 2 independent experiments, 2-3 mice per experimental group.
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Figure S6. Aipfl/fl Cre+ mice have no differences in ERK or SYK phosphorylation following BCR
stimulation; related to Figure 3
IgD- B cells from Aipfl/fl Cre+ and Cre- mice were stimulated with anti-IgM (10µg/ml) and examined for the
expression of phosphorylated (A) ERK and (B) SYK from 5 to 60 minutes post-stimulation. Grey histograms
show expression at time 0 (T0). Data expressed as percentage from time 0. Results are from two
independent experiments with 1-2 mice per experimental group.
